Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 26, 2024

The human gastrointestinal (GI) tract microbiome is a complex and all-encompassing ecological system of trillions microorganisms. It plays vital role in digestion, disease prevention, overall health. When this delicate balance disrupted, it can lead to various health issues. Fecal microbiota transplantation (FMT) an emerging therapeutic intervention used as adjuvant therapy for many diseases, particularly those with dysbiosis their underlying cause. Its goal restore by transferring fecal material from healthy donors the recipients. FMT has impressive reported cure rate between 80% 90% become favored treatment diseases. While may have generally mild moderate transient adverse effects, rare severe complications underscore importance rigorous donor screening standardized administration. enormous potential practical approach; however, additional research required further determine its clinical utilization, well safety efficiency different patient populations. This comprehensive literature review offers increased confidence effectiveness several diseases affecting intestines other systems, including diabetes, obesity, inflammatory autoimmune illness, conditions.

Language: Английский

---

Nutritional optimization of fecal microbiota transplantation in humans: a scoping review

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 8, 2025

Diet constitutes a major source of nutrient flow to the gut microbes. As such, it can be used help shape microbiome. Fecal microbiota transplantation (FMT) is an increasingly promising therapy in disease states beyond recurrent Clostridioides difficile infection, but diet largely overlooked for its potential optimize this therapy. Therefore, aim scoping review present literature landscape that captures pre- and post-FMT dietary intake humans, identify research gaps, provide recommendations future research. A comprehensive search strategy was developed searches were run five databases. Studies included if they discussed adults who underwent FMT any recognized treatment indication had as study objective, encompassed studies with interventions foods supplements. The initial screening identified total 7721 articles, which 18 met inclusion criteria review. heterogeneous, taken together, introduce framework defines important nutritional considerations both donors recipients period around dosing. This summarized highlights opportunities available develop FMT-based precision nutrition strategies clinical efficacy.

Language: Английский

---

Rethinking the classification of non‐digestible carbohydrates: Perspectives from the gut microbiome

Comprehensive Reviews in Food Science and Food Safety, Journal Year: 2024, Volume and Issue: 23(6)

Published: Oct. 22, 2024

Abstract Clarification is required when the term “carbohydrate” used interchangeably with “saccharide” and “glycan.” Carbohydrate classification based on human digestive enzyme activities brings clarity to energy supply function of digestible sugars starch. However, categorizing structurally diverse non‐digestible carbohydrates (NDCs) make dietary intake recommendations for health promotion remains elusive. In this review, we present a summary strengths weaknesses traditional dichotomic classifications carbohydrates, which were introduced by food chemists, nutritionists, microbiologists. parallel, discuss current consensus commonly terms NDCs such as “dietary fiber,” “prebiotics,” “fermentable glycans” highlight their inherent differences from perspectives gut microbiome. Moreover, provide historical perspective development novel concepts microbiota‐accessible microbiota‐directed fiber, targeted prebiotics, glycobiome. Crucially, these proposed multidisciplinary scholars help distinguish interactions between summary, created inability enzymes fails denote Considering that microbiome possesses sophisticated systems harvest NDCs, subclassification should be realigned metabolism various microbes, particularly health‐promoting microbes. Such rigorous categorizations facilitate microbiome‐targeted therapeutic strategies incorporating specific types NDCs.

Language: Английский

---

The Functions of Major Gut Microbiota in Obesity and Type 2 Diabetes

Metabolites, Journal Year: 2025, Volume and Issue: 15(3), P. 167 - 167

Published: March 1, 2025

Background: Gut microbiomes play a vital role in maintaining whole-body metabolic homeostasis. It has gained significant attention recent years due to advancements genome sequencing technologies and deeper understanding of its relationship with obesity. However, the specific ways which different microorganisms directly or indirectly influence host obesity, as well underlying mechanisms, remain uncertain because complexity gut microbiota composition. Methods: In this review, we summarize roles major phyla such Bacteroidetes, Firmicutes, Proteobacteria, Verrucomicrobia obesity type 2 diabetes based on studies published past five PubMed Google Scholar. The current therapeutic strategies associated are also explored from clinical trials, challenges future directions discussed. Results Conclusions: This review will provide functions diabetes, could lead more individualized effective treatments for diseases.

Language: Английский

---

Fecal microbiota transplantation-current perspective on human health

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 14, 2025

Recently, microbiome medicine has attracted the attention of researchers. While this rapidly growing medical approach for various diseases and disorders is changing paradigm, it imperative to weigh both its benefits associated risk factors. For instance, manipulation gut microbiota (GM) positive effects on metabolic neurodegenerative diseases. Notably, fecal transplantation (FMT), a complex method, shown promise; however, many doubt feasibility without adverse human health. Given number clinical trials investigating FMT treatment disorders, review summarizes recent findings impact This responses with their reversal gastrointestinal infections, behavioral changes, immune responses. Additionally, discusses role in antimicrobial resistance co-supplementation health, safety, potential risks, limitations, prospects, recommendations. Although does not cover all studies database, searched terms health are sufficient provide summary current perspective.

Language: Английский

---

Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: March 25, 2025

Fecal microbiota transplantation (FMT) represents a therapeutic approach that directly regulates the gut of recipients, normalizes its composition and reaping rewards. Currently, in addition to general application treating Clostridium difficile ( C. ) infection (CDI), FMT treatment has also been extended fields other gastrointestinal diseases, infections, gut-liver or gut-brain axis disorders, metabolic diseases cancer, etc. Prior FMT, rigorous donor screening is essential reduce occurrence adverse events. In addition, it imperative evaluate whether recipient can safely effectively undergo treatment. However, efficacy influenced by complex interactions between recipient, degree engraftment not necessarily positively related with success rate FMT. Furthermore, an increasing number novel factors affecting outcomes are being identified recent clinical trials animal experiments, broadening our understanding This article provides comprehensive review scenarios influencing safety from aspects both donors summarizes how these emerging regulatory be combined predict patients undergoing

Language: Английский

---

Multiomics Analyses of Citrus aurantium L. Var. Amara and Ginger Reveals Lipid Metabolism, Bile Acid Biosynthesis, and Gut Microbiome Rebalance Supporting Their Anti‐Obesity Effects

Biomedical Chromatography, Journal Year: 2025, Volume and Issue: 39(5)

Published: March 27, 2025

ABSTRACT Both the flower of Citrus aurantium L. var. amara (CAVA) and rhizome Zingiber officinale Roscoe (ginger) are food medicinal homologous plants that have been used in China for aiding gastric digestion preventing obesity. However, combinatorial use two on obesity remains elusive. Our endeavor aimed to identify optimal synergistic ratio between CAVA ginger explore underlying mechanism their anti‐obesity effects. Aqueous extracts were prepared separately then combined into nine different ratios. The constituents unambiguously characterized by employing LC–MS. High‐fat diet (HFD)–induced obese C57BL/6J mice established administered with combinations CAVA‐G 6 weeks. trajectory mice's body weights was analyzed. Besides, hematoxylin eosin (HE) staining liver oil red O adipose tissue performed. ELISA assay employed measure serum levels total cholesterol (TC), triglyceride (TG), low‐density lipoprotein (LDL‐C), high‐density (HDL‐C). Moreover, metabolic profiling conducted through UPLC‐Q‐TOF/MS analysis. Gut microbiota analysis performed via 16S rRNA gene sequencing. Pattern recognition Pearson correlation pinpoint key endogenous metabolites microbiota. Two groups combination treatment (C3 A1) significantly prevented increase weight mice. According our analysis, best effect achieved when 37:63. TC LDL‐C dramatically decreased C3 group, whereas level TG reduced A1 group. Interestingly, HDL‐C increased Compared model a 16 25 biomarkers identified A1, respectively. These mainly implicated lipid metabolism primary bile acid biosynthesis. abnormal diversity gut induced HFD feeding. Treatment or relative abundance Akkermansia Novosphingobium , while reducing Dorea Bacteroides Roseburia . Of note, this is first report involved findings will layer foundation usage

Language: Английский

---

Tangeretin modulates gut microbiota metabolism and macrophage immunity following fecal microbiota transplantation in obesity

Journal of Food Science, Journal Year: 2025, Volume and Issue: 90(4)

Published: April 1, 2025

Obesity, characterized by excessive body fat, is a leading preventable cause of death globally and represents one the most critical public health challenges 21st century. This study aimed to investigate action tangeretin on gut microbiota metabolism inflammation in high-fat diet (HFD)-induced obese mice. A model obesity was established using 6-week-old male C57BL/6J mice fed with HFD, which were then used for treatment (20 mg/kg/mice/day) or antibiotic (Abx). The results showed that intervention alleviated fat deposition disorder cellular structural integrity group. significant increase levels lipid (glycerol, triglyceride, total cholesterol), inflammatory factors (IL-6 TNF-α), F4/80 expression both serum adipose tissues. Following treatment, lipid, factors, ratio + CD206 macrophages decreased tissue. 16S rRNA sequencing LC-MS/MS analysis revealed HFD-induced interacting microbiota, particularly influencing Parabacteroides, Blautia, Parasutterella, amino acids such as threonine, isoleucine, leucine, phenylalanine, arginine, glutamine, L-tryptophan, tyrosine. Abx-mediated clearance blocked abrogated therapeutic effects Fecal transplantation (FMT) proved clearing Abx beneficial FMTHFD+Tangeretin intervention. These findings suggested improved regulating modulating macrophage activation via microbiota.

Language: Английский

---

Clostridium butyricum Ameliorates Post-Gastrectomy Insulin Resistance by Regulating the mTORC1 Signaling Pathway Through the Gut-Liver Axis

Microbiological Research, Journal Year: 2025, Volume and Issue: unknown, P. 128154 - 128154

Published: April 1, 2025

Language: Английский

---

Precision microbiota therapy for IBD: premise and promise

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 7, 2025

Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases the intestine that includes subtypes ulcerative colitis (UC) and Crohn's (CD) currently has no cure. While IBD results from complex interplay between genetic, environmental, immunological factors, sequencing advances over last 10-15 years revealed signature changes in gut microbiota contribute to pathogenesis IBD. These findings highlight as disease target for microbiome-based therapies, with potential treat underlying microbial provide adjuvant therapy emerging advanced therapies Building on success fecal transplantation (FMT) Clostridioides difficile infection, targeting have emerged promising approaches treating IBD; however, unique aspects need more precision approach microbiome therapeutics leverage recipient donor selection, diet xenobiotics, strain-specific interactions enhance efficacy safety therapy. This review focuses both pre-clinical clinical studies support premise aims framework development optimize outcomes patients

Language: Английский

---